Alpha 2.0
Login Register
» Authors » Mitchell J Frederick

Mitchell J Frederick

Explore the profile of Mitchell J Frederick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 4445
Followers 0
Related Specialties
Oncology
Biochemistry
Molecular Biology
Top 10 Co-Authors
Jeffrey N Myers
Curtis R Pickering
Jing Wang
Adel K El-Naggar
Gary L Clayman
Faye M Johnson
Mei Zhao
Abdullah A Osman
Li Shen
Vlad C Sandulache
Published In
Clin Cancer Res
Head Neck
Cancer Res
Mol Cancer Ther
Arch Biochem Biophys
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, et al.
Oral Oncol . 2024 Apr; 153:106729. PMID: 38663156
Background: Extranodal extension (ENE) of lymph node metastasis is one of the most reliable prognostic indicators for patients with locally advanced oral cancer. Although multiple reports have found a close...
2.
Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation
Castro P, Corredor G, Koyuncu C, Nordstrom L, Tiji M, Leavitt T, et al.
Head Neck Pathol . 2023 Nov; 17(4):952-960. PMID: 37995073
Objective: Oropharyngeal squamous cell carcinoma (OPSCC) recurrence is almost universally fatal. Development of effective therapeutic options requires an improved understanding of recurrent OPSCC biology. Methods: We analyzed paired primary-recurrent OPSCC...
3.
Recurrent oropharyngeal squamous cell carcinomas maintain anti-tumor immunity and multinucleation levels following completion of radiation
Castro P, Corredor G, Koyuncu C, Nordstrom L, Tiji M, Leavitt T, et al.
Res Sq . 2023 Sep; PMID: 37674722
Objective: Oropharyngeal squamous cell carcinoma (OPSCC) recurrence is almost universally fatal. Development of effective therapeutic options requires an improved understanding of recurrent OPSCC biology. Methods: We analyzed paired primary-recurrent OPSCC...
4.
Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients
Koyuncu C, Frederick M, Thompson L, Corredor G, Khalighi S, Zhang Z, et al.
Oral Oncol . 2023 Jun; 143:106459. PMID: 37307602
Objectives: Matching treatment intensity to tumor biology is critical to precision oncology for head and neck squamous cell carcinoma (HNSCC) patients. We sought to identify biological features of tumor cell...
5.
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state
Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, et al.
Br J Cancer . 2023 Apr; 128(11):2013-2024. PMID: 37012319
Background: Cisplatin (CDDP) is a mainstay treatment for advanced head and neck squamous cell carcinomas (HNSCC) despite a high frequency of innate and acquired resistance. We hypothesised that tumours acquire...
6.
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Osman A, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, et al.
Clin Cancer Res . 2023 Jan; 29(7):1344-1359. PMID: 36689560
Purpose: Cisplatin (CDDP)-based chemotherapy is a first-line treatment for patients with advanced head and neck squamous cell carcinomas (HNSCC), despite a high rate of treatment failures, acquired resistance, and subsequent...
7.
Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma
Shah P, Sambandam V, Fernandez A, Zhao H, Mazumdar T, Shen L, et al.
Cancer Res . 2022 Sep; 82(23):4444-4456. PMID: 36169922
Significance: Aurora B signaling facilitates resistance to PI3K inhibition in head and neck squamous cell carcinoma, suggesting that combined inhibition of PI3K and Aurora kinase is a rational therapeutic strategy...
8.
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
Johnson F, Janku F, Gouda M, Tran H, Kawedia J, Schmitz D, et al.
Oncologist . 2022 Sep; 27(12):1004-e926. PMID: 36124629
Background: PI3K/mTOR inhibition leads to apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC) cells. We tested the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC....
9.
Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response
Ahmed K, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas M, et al.
J Immunother Cancer . 2022 Aug; 10(8). PMID: 36002187
Background: The existence of immunologically 'cold tumors' frequently found across a wide spectrum of tumor types represents a significant challenge for cancer immunotherapy. Cold tumors have poor baseline pan-leukocyte infiltration,...
10.
Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers
Ghosh S, Mazumdar T, Xu W, Powell R, Stephan C, Shen L, et al.
Clin Cancer Res . 2022 Aug; 28(20):4479-4493. PMID: 35972731
Purpose: Human papillomavirus (HPV) causes >5% of cancers, but no therapies uniquely target HPV-driven cancers. Experimental Design: We tested the cytotoxic effect of 864 drugs in 16 HPV-positive and 17...